Rainmed Medical (HKSE:02297) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02297 Rainmed Medical Ltd HKSE:02297
49 GF Score
Price HK$0.23
GF Value HK$0.08
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Rainmed Medical Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HKSE:02297
49GF Score
Rainmed Medical Ltd HKSE:02297
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rainmed Medical (HKSE:02297) Overvalued in 2026?

Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued. The current stock price of HK$0.23 is trading 181.3% above its estimated GF Value™ of HK$0.08. GuruFocus considers Rainmed Medical to be Significantly Overvalued.

Key valuation signals for HKSE:02297:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: HK$0.08 vs. price of HK$0.23 (181.3% above fair value)
  • GF Score™: 49/100 with 9 warning signs

No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rainmed Medical Business Description

Address No. 99, Jinji Lake Avenue, Room NW-05-502, Building 31, Nanopolis Suzhou, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
49GF Score

Get the complete analysis for HKSE:02297

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.23
Price
HK$0.08
GF Value